Terumo (OTCMKTS:TRUMY) Announces Earnings Results
by Scott Moore · The Cerbat GemTerumo (OTCMKTS:TRUMY – Get Free Report) issued its earnings results on Friday. The company reported $0.11 EPS for the quarter, meeting the consensus estimate of $0.11, Zacks reports. Terumo had a net margin of 11.74% and a return on equity of 9.01%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.84 billion.
Terumo Trading Up 4.1%
TRUMY opened at $12.68 on Friday. The firm’s fifty day moving average is $13.08 and its two-hundred day moving average is $14.00. The firm has a market cap of $18.70 billion, a PE ratio of 20.79 and a beta of 0.62. Terumo has a twelve month low of $12.08 and a twelve month high of $19.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.89 and a current ratio of 1.51.
Wall Street Analysts Forecast Growth
TRUMY has been the subject of a number of analyst reports. Nomura raised Terumo to a “hold” rating in a research note on Tuesday, February 24th. Zacks Research upgraded Terumo to a “hold” rating in a report on Thursday, April 9th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Terumo presently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on Terumo
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
See Also
- Five stocks we like better than Terumo
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising